Expert Pitch

Second stimulus bill needed to prevent additional job losses

Cornell University
11-Sep-2020 1:15 PM EDT, by Cornell University

On Thursday, the Senate failed to pass a pared-down coronavirus relief package and the U.S. Department of Labor reported more than 857,000 workers filed new unemployment claims in the past week.

Russell Weaver, an economic geographer with Cornell University’s School of Industrial and Labor Relations (ILR) Buffalo Co-Lab says an increase in job losses are likely if appropriate actions are not taken to stimulate the economy.

Bio: https://www.ilr.cornell.edu/people/russell-weaver

Weaver says: 

“State and local governments are facing huge revenue shortfalls that will necessitate budget cuts. Those cuts could result in additional public sector job losses at a time of elevated demand for public sector services. Similarly, new weekly unemployment insurance (UI) claims are ticking up again, as are cases of COVID-19 both nationally and across New York State.

“There is compelling evidence that the extended $600/week UI benefits substantially lessened the pandemic's negative economic impacts, as they enabled households to continue to spend and pay rent despite unprecedented job losses. The expiration of those benefits will likely coincide with reduced household spending on average, particularly among working class households. Lower consumer spending will mean lower sales tax revenues for state and local governments, and lower revenues for many private sector businesses, large and small. 

“In both cases, public and private, prospects of lower revenues mean that additional job losses are possible if appropriate actions are not taken to stimulate the economy. Renewing the extra UI benefits and providing additional direct cash support to households are two components of a people-centered recovery. Additional federal aid to state and local governments is another one.” 

- 30 -




Filters close

Showing results

110 of 4149
Released: 30-Nov-2020 9:45 AM EST
Rutgers Leading Coronavirus Therapeutic Clinical Trial
Rutgers University-New Brunswick

Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Dec-2020 11:00 AM EST Released to reporters: 30-Nov-2020 8:40 AM EST

A reporter's PressPass is required to access this story until the embargo expires on 1-Dec-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: COVID-19 Peer Hub combats vaccine avoidance amid pandemic
Released: 27-Nov-2020 8:05 AM EST
COVID-19 Peer Hub combats vaccine avoidance amid pandemic
University of South Australia

UniSA researchers are evaluating a new vaccination education initiative – the COVID-19 Peer Hub – to help immunisation and public health professionals to tackle the emerging dangers of vaccine hesitancy amid the pandemic.

Newswise: Long-Term Impacts of COVID-19: Your Mental Health
Released: 25-Nov-2020 2:15 PM EST
Long-Term Impacts of COVID-19: Your Mental Health
Cedars-Sinai

The COVID-19 pandemic has shaped more than half a year of our lives, canceling plans, upending livelihoods and causing feelings of grief, stress and anxiety. And Cedars-Sinai mental health experts say the pandemic could be shaping our mental health well into the future.

Released: 25-Nov-2020 12:45 PM EST
SARS-CoV-2 mutations do not appear to increase transmissibility
University College London

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

Newswise: COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
Released: 25-Nov-2020 11:05 AM EST
COVID-19 vaccine candidate tested preclinically at UAB nears first clinical test in people
University of Alabama at Birmingham

Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

Released: 25-Nov-2020 11:05 AM EST
BIDMC researchers reveal how genetic variations are linked to COVID-19 disease severity
Beth Israel Lahey Health

New research BIDMC-led sheds light on the genetic risk factors that make individuals more or less susceptible to severe COVID-19.

Newswise: blog-pandemic-scenario-planning-lg-feature2.jpg
Released: 25-Nov-2020 11:05 AM EST
Pandemic Ups Game on Scenario Planning in The Arts
Wallace Foundation

Researcher/Author of new toolkit and report seeks to help arts and culture organizations add scenario planning to their strategic toolbox

Released: 25-Nov-2020 10:30 AM EST
Young people's anxiety levels doubled during first COVID-19 lockdown, says study
University of Bristol

The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol.

Newswise: 249837_web.jpg
Released: 25-Nov-2020 10:20 AM EST
Tracking COVID-19 trends in hard-hit states
Louisiana State University

Currently, there are over 10 million confirmed cases and more than 240,000 casualties attributed to COVID-19 in the U.S.


Showing results

110 of 4149

close
0.97955